{"filing":{"accession_number":"0001213900-26-104647","cik":"0001937993","ticker":"CVKD","company_name":"Cadrenal Therapeutics, Inc.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-24","primary_document":"ea0306613-8k_cadrenal.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1937993/000121390026104647/ea0306613-8k_cadrenal.htm"},"events":[{"id":35734,"run_id":32933,"accession_number":"0001213900-26-104647","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Cadrenal Therapeutics held its 2026 Annual Meeting on September 24, 2026, with shareholders voting on five proposals: election of Class I director Quang X. Pham, ratification of WithumSmith+Brown as independent auditor, approval of Amendment No. 2 to the 2022 Successor Equity Incentive Plan (increasing share pool by 323,542 shares to 1,000,000 total), approval of warrant exercise issuance, and adjournment authority. The detailed voting results confirm shareholder approval of the equity plan amendment and dilutive warrant issuance.","company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39895,"accession_number":"0001213900-26-104647","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of Amendment No. 2 to the 2022 Successor Equity Incentive Plan, which increases the share pool available for equity awards by 323,542 shares to a total of 1,000,000 shares. This is a compensatory arrangement amendment affecting the availability of equity grants to officers and directors, falling squarely within exec_compensation. The amendment was approved at the 2026 Annual Meeting and materially expands the capacity for future equity-based compensation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:06:57.345551+00:00","company_name":"","ticker":null,"filing_date":""},{"id":39896,"accession_number":"0001213900-26-104647","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the final voting results from Cadrenal Therapeutics' 2026 Annual Meeting held on September 24, 2026, covering five proposals: election of a Class I director (Quang X. Pham), ratification of WithumSmith+Brown as independent auditor, approval of Amendment No. 2 to the 2022 Plan increasing available shares, approval of warrant exercise issuance, and adjournment authority. The detailed vote tallies for each proposal are material to investors as they confirm shareholder approval of equity plan amendments and dilutive warrant issuances.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:06:57.345551+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39895,"accession_number":"0001213900-26-104647","item_number":"5.02","item_title":"Departure of Directors or Certain","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of Amendment No. 2 to the 2022 Successor Equity Incentive Plan, which increases the share pool available for equity awards by 323,542 shares to a total of 1,000,000 shares. This is a compensatory arrangement amendment affecting the availability of equity grants to officers and directors, falling squarely within exec_compensation. The amendment was approved at the 2026 Annual Meeting and materially expands the capacity for future equity-based compensation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:06:57.345551+00:00","company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","filing_date":"2026-09-29"},{"id":39896,"accession_number":"0001213900-26-104647","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure reports the final voting results from Cadrenal Therapeutics' 2026 Annual Meeting held on September 24, 2026, covering five proposals: election of a Class I director (Quang X. Pham), ratification of WithumSmith+Brown as independent auditor, approval of Amendment No. 2 to the 2022 Plan increasing available shares, approval of warrant exercise issuance, and adjournment authority. The detailed vote tallies for each proposal are material to investors as they confirm shareholder approval of equity plan amendments and dilutive warrant issuances.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T20:06:57.345551+00:00","company_name":"Cadrenal Therapeutics, Inc.","ticker":"CVKD","filing_date":"2026-09-29"}]}